Results 91 to 100 of about 14,162 (232)
Hidradenitis Suppurativa and Post‐Arthroplasty Wound Complications
International Journal of Dermatology, EarlyView.
Dominique Digiacomo +4 more
wiley +1 more source
Delphi consensus: First‐line use of biologics and small molecules in hidradenitis suppurativa
This Delphi Consensus study identified upgrade criteria for the use of biologics and small molecules as first‐line therapy in hidradenitis suppurativa (HS). European HS experts evaluated 16 clinical scenarios, voting on eligibility for therapy escalation.
Georgios Nikolakis +54 more
wiley +1 more source
Hidradenitis suppurativa, or acne inversa, is a chronic, recurrent inflammatory disease of the skin and subcutaneous tissue, and is characterised by painful, recurrent nodules that results in abscesses and formation of chronic draining sinus tracts and ...
Shih Jia Janice Tan, Hsien Ts’ung Tay
doaj
A meta‐analysis was conducted comparing the efficacy of biologics for the treatment of hidradenitis suppurativa (HS) for 12–16 weeks. Based on the SUCRA, bimekizumab was ranked the most efficacious treatment compared with secukinumab and adalimumab for all assessed efficacy outcomes, positioning it as the best treatment across biologic‐naïve and ...
Haley B. Naik +9 more
wiley +1 more source
Intermammary Hidradenitis Suppurativa [PDF]
Philippe, Guillem +1 more
openaire +2 more sources
Cancer and hidradenitis suppurativa
Patients with hidradenitis suppurativa (HS) have an increased risk of developing cancer. This includes not only hematologic malignancies and solid tumors but also cutaneous squamous cell carcinoma (SCC) originating within the HS lesions. The development of SCC is most commonly associated with Caucasian men who smoke and have severe gluteal or perianal ...
Philip R, Cohen +2 more
openaire +3 more sources
Disfiguring Hidradenitis Suppurativa of the Face [PDF]
Gianmarco Capasso +2 more
openalex +1 more source
A matching‐adjusted indirect treatment comparison (MAIC) was conducted, comparing approved biologics for long‐term (48–52 weeks) treatment of moderate‐to‐severe hidradenitis suppurativa (HS). Using weighted patient‐level trial data allowed re‐estimation of relative bimekizumab efficacy compared with aggregate secukinumab and adalimumab trial data ...
Thrasyvoulos Tzellos +9 more
wiley +1 more source
Skin Homeostasis is Impaired in Hidradenitis Suppurativa Lesions: A Comparative Study
Introduction: Hidradenitis suppurativa (HS) is a chronic skin disease whose impact on skin homeostasis has not been adequately studied at present. Knowledge about how skin function changes in these patients, and could be of interest not only to improve ...
A. Soto-Moreno +4 more
doaj +1 more source
Immunopathogenesis of hidradenitis suppurativa and response to anti–TNF-α therapy [PDF]
Margaret M. Lowe +15 more
openalex +1 more source

